Skip to content
10-Q

Quarterly Report

INTERPACE BIOSCIENCES, INC. IDXG

0001641172-25-009275

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 2, 2025 4.42M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $1.2M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $1.46M
Current Liabilities Q1 2025 · Mar 31, 2025 $8.68M
Current Liabilities Q1 2025 · Dec 31, 2024 $10.62M
Total Liabilities Q1 2025 · Mar 31, 2025 $15.08M
Total Liabilities Q1 2025 · Dec 31, 2024 $17.01M
Current Assets Q1 2025 · Mar 31, 2025 $11.65M
Current Assets Q1 2025 · Dec 31, 2024 $11.77M
Total Assets Q1 2025 · Mar 31, 2025 $14.49M
Total Assets Q1 2025 · Dec 31, 2024 $14.79M
Shares Diluted Q1 2025 · Mar 31, 2024 4.38M sh
Capex Q1 2025 · Mar 31, 2024 $28K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$58K
Stockholders Equity restated Q1 2025 · Mar 31, 2024 −$54.77M
Stockholders Equity restated Q1 2025 · Dec 31, 2023 −$55.54M
Eps Diluted restated Q1 2025 · Mar 31, 2024 $0.16
Eps Basic restated Q1 2025 · Mar 31, 2024 $0.16
Sga Expense Q1 2025 · Mar 31, 2024 $2.24M
Rd Expense Q1 2025 · Mar 31, 2024 $137K
Net Income restated Q1 2025 · Mar 31, 2024 $708K
Operating Income restated Q1 2025 · Mar 31, 2024 $1.11M
Gross Profit restated Q1 2025 · Mar 31, 2024 $6.31M
Cost Of Revenue restated Q1 2025 · Mar 31, 2024 $3.87M
Revenue restated Q1 2025 · Mar 31, 2024 $10.18M